论文部分内容阅读
ImCloneSystems/MerckKGaA/布迈 施贵宝公司联合开发的表皮生长因子受体 (EGFR)靶向单克隆抗体西妥昔单抗 (cetuximab ,Erbitux)与放疗联用的Ⅲ期临床试验显示 ,它能改善局部恶化头颈癌患者的存活。这项涉及 4 2 4名患者的试验是继OSIPharma ceuticals/Genentech/Roche公司的
Phase III clinical trial of ImCloneSystems / MerckKGaA / EGFR targeted monoclonal antibody cetuximab (Erbitux) in combination with radiotherapy showed that it can improve the local deterioration Head and neck cancer patients survive. The trial involving 424 patients followed OSIPharma ceuticals / Genentech / Roche